



### DISEASE BURDEN

In 2022, 39 million people globally were living with HIV and 1.3 million people became newly infected, most of which occurred in LMICs.

### CLINICAL RELEVANCE

The VH4524184 is a new third-generation integrase strand transfer inhibitor (INSTI) in phase II, with a superior resistance profile compared to second-generation INSTIs. It could be important in case of increased global DTG resistance.

### INTELLECTUAL PROPERTY LANDSCAPE

VH4524184



### SERVICE DELIVERY ENABLERS

Assessment in progress

### REGULATORY

Assessment in progress

### MANUFACTURING

Assessment in progress

### MARKET

Assessment in progress